B
Barry R. Davis
Researcher at University of Texas at Austin
Publications - 351
Citations - 50989
Barry R. Davis is an academic researcher from University of Texas at Austin. The author has contributed to research in topics: Chlorthalidone & Amlodipine. The author has an hindex of 78, co-authored 342 publications receiving 47899 citations. Previous affiliations of Barry R. Davis include Tulane University & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study.
Amy I. Lynch,Eric Boerwinkle,Barry R. Davis,Charles E. Ford,John H. Eckfeldt,Catherine Leiendecker-Foster,Donna K. Arnett +6 more
TL;DR: There was evidence of pharmacogenetic effects of FGB-455 on stroke, ESRD, and mortality, suggesting that relative to those homozygous for the common allele, variant allele carriers of the FGB gene at position −455 have a better outcome if randomized to lisinopril than chlorthalidone or amlodipine.
Journal ArticleDOI
Absence of an interaction between the angiotensin-converting enzyme insertion-deletion polymorphism and pravastatin on cardiovascular disease in high-risk hypertensive patients: the Genetics of Hypertension-Associated Treatment (GenHAT) study.
Anke Hilse Maitland-van der Zee,Anke Hilse Maitland-van der Zee,Eric Boerwinkle,Donna K. Arnett,Barry R. Davis,Catherine Leiendecker-Foster,Michael B. Miller,OH Klungel,Charles E. Ford,John H. Eckfeldt +9 more
TL;DR: No evidence is found that the ACE ID genotype was a major modifier of the efficacy of pravastatin in reducing the risk of cardiovascular events.
Journal ArticleDOI
Electrocardiographic left ventricular hypertrophy predicts cardiovascular morbidity and mortality in hypertensive patients: the allhat study
Casper N. Bang,Elsayed Z. Soliman,Lara M. Simpson,Barry R. Davis,Richard B. Devereux,Peter M. Okin +5 more
Journal ArticleDOI
Prevalence and correlates of symptomatic peripheral atherosclerosis in individuals with coronary heart disease and cholesterol levels less than 240 mg/dL: baseline results from the Cholesterol and Recurrent Events (CARE) Study.
TL;DR: The presence of clinically evident diffuse atherosclerosis is common and is associated with several modifiable risk factors and early identification of these individuals could affect treatment and clinical outcomes.
Journal ArticleDOI
Cardiovascular risk assessment: Addition of CKD and race to the Framingham equation
Paul E. Drawz,Sarah Baraniuk,Barry R. Davis,Clinton D. Brown,Pedro J. Colon,Aloysius B. Cujyet,Richard A. Dart,James F. Graumlich,Mario A. Henriquez,Jamaluddin Moloo,Mohammed G. Sakalayen,Debra L. Simmons,Carol Stanford,Mary Ellen Sweeney,Nathan D. Wong,Mahboob Rahman +15 more
TL;DR: The addition of CKD status and stratification by race does not improve risk prediction in high-risk hypertensive patients, and the value of the Framingham equation in predicting cardiovascular risk is unclear.